Vascular Senescence and Atherosclerotic Plaque Vulnerability

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorNiguarda Hospital

About this trial

Chronological aging significantly contributes to structural and functional alterations in the vasculature, making it a major risk factor for atherosclerotic disease and its acute thrombotic events. DNA damage, including telomeric, non-telomeric, and mitochondrial damage, is recognized as a key initiator of vascular aging and atherogenesis. There is abundant evidence indicating the presence of oxidative DNA lesions, telomere erosion, and mitochondrial DNA damage in both experimental and human plaques, as well as in the peripheral cells of atherosclerotic patients.

It is increasingly evident that genomic instability activates signaling pathways that lead to a multitude of pathophysiological cellular and molecular changes. These changes promote inflammation, apoptosis, autophagy, and ultimately, cellular senescence, accompanied by the "senescence-associated secretory phenotype" (SASP). However, the precise mechanisms linking the DNA damage response (DDR) to senescence, SASP in vascular cells, and the pathogenesis of atherosclerosis and vulnerable atheroma are yet to be fully understood. Additional research is needed to delineate the underlying mechanisms through which mitochondrial dysfunction influences telomere length and vice versa, and how their interaction contributes to the vascular aging process. Progress in this area has the potential to uncover therapeutic targets and novel, more precise diagnostic, and prognostic indicators.

The objectives of the VICTORIA study are to examine the levels of aging-related non-coding RNA deregulation (specifically lncRNA TERRA and mitomiR) and peripheral markers of cell aging (including telomere length and mitochondrial DNA content) across the various spectra of angina pectoris (stable angina, unstable angina, NSTEMI, and STEMI). Additionally, the study aims to determine whether these markers are correlated with vulnerable plaque characteristics and major adverse cardiovascular events.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with acute coronary syndromes (unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI))

stable angina

non-angiographically significant coronary diseases recovered for elective diagnostic or interventional procedures

Disqualifiers

cardiac shock

congestive heart failure

end stage renal diseases

coronary artery bypass graft

Trial population

Patients with acute or chronic coronary syndromes

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Several biomarkers

    Other intervention

    Telomere length Mitochondrial DNA copy number (mtDNAcn) MitomiR long non-coding (lnc) RNA TERRA pro-oxidant cytokines \& chemokines

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: Patients with coronary artery diseases1 intervention

Trial outcomes

Primary outcomes

1

Telomere length

Telomere length (LTL) is an index of genetic instability and senescence. LTL is measured in the DNA (extracted from blood leucocytes) by RT-PCR. Measure unit: 2\^(-ddct) or kilobases

Time frame
T0, at the enrollment

Secondary outcomes

1

Mitochondrial DNA copy number (mtDNAcn)

Indices of mitochondrial deregulation Measure unit: 2\^(-ddct) or kilobases

Time frame
T0, at the enrollment
2

MitomiR

Indices of mitochondrial deregulation

Time frame
T0, at the enrollment
3

Long non-coding (lnc) RNA TERRA

modulator of telomerase

Time frame
T0, at the enrollment
4

pro-oxidant cytokines

expression of SASP phenotype. - picograms/ml

Time frame
T0, at the enrollment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Niguarda Hospital

Lead sponsor

Istituto di Fisiologia Clinica CNR

Collaborator